Connectin is a hip and joint supplement for dogs made by inClover Research, a Boulder, Colorado company, built around glucosamine HCl, a porcine-sourced chondroitin and hyaluronic acid blend, and nine herbs. It is sold as a powder, soft chews, crunchy tablets, and a concentrated large-dog chew. inClover markets it as “the only joint supplement clinically proven by independent researchers to help support comfort and mobility in an average of 15 days” — a claim that traces back to a real trial, but one whose published write-up does not appear in PubMed and does not report a 15-day endpoint.
The short answer: Connectin is a fully disclosed, NASC-participating joint supplement whose per-serving amounts are printed openly — which is more than many competitors offer. But its chondroitin and hyaluronic acid are listed only as a combined “mucopolysaccharides” figure, its herbal extracts carry no standardisation data, and the “clinically proven in 15 days” line rests on a 2014 trade-publication write-up rather than a peer-reviewed, indexed paper. Treat it as a reasonable, transparent option — not as a proven treatment.
Who makes Connectin, and what is it for?
inClover Research has sold pet supplements since 1996 from Boulder, Colorado. Its Safety & Quality page states that its quality systems include cGMP, AAFCO, FDA, HACCP and NASC independent audits, and it displays the NASC Quality Seal. That matters: the seal signifies a company has been audited against specific standards, which is meaningful in a category with almost no pre-market regulation.
Connectin is positioned for dogs with age-related stiffness and for younger dogs whose owners want joint support early. It is a nutritional supplement, not a medication, and not a substitute for veterinary diagnosis or for the drugs vets use to manage arthritis pain.
What is actually in Connectin?
This is where Connectin earns real credit. The official Canine Connectin product page publishes complete active-ingredient panels for all four formats, with per-serving milligrams for every active — a level of disclosure a surprising number of brands skip.
Here are the published per-serving amounts, quoted from the label panels:
| Active ingredient | Powder (per 8.5 g scoop) | Soft chew (per 4 g chew) | Large-dog chew (per 4 g chew) | Crunchy tablet (per 3 g tablet) |
|---|---|---|---|---|
| Glucosamine HCl 99%+ pure (shellfish) | 625 mg | 500 mg | 750 mg | 500 mg |
| Mucopolysaccharides (porcine chondroitin sulfate & hyaluronic acid) | 1200 mg | 250 mg | 350 mg | 250 mg |
| Yucca root | 1200 mg | 135 mg | 135 mg | 135 mg |
| Alfalfa | 500 mg | 85 mg (extract) | 85 mg (extract) | 85 mg (extract) |
| Nettle leaf | 300 mg | 100 mg | 100 mg | 100 mg |
| Devil’s claw | 100 mg | 6.8 mg (extract) | 6.8 mg (extract) | 6.8 mg (extract) |
| Celery seed | 50 mg | 25 mg | 25 mg | 25 mg |
| Black cohosh root | 50 mg | 25 mg | 25 mg | 25 mg |
| Ginger root | 50 mg | 12 mg (extract) | 12 mg (extract) | 12 mg (extract) |
| Turmeric root | 50 mg | 2.5 mg (extract) | 2.5 mg (extract) | 2.5 mg (extract) |
| Cayenne pepper | 5 mg | 2.5 mg | 2.5 mg | 2.5 mg |
One point most reviews miss: the formats are not interchangeable. On inClover’s own weight chart, a 50 lb dog on maintenance takes 3/4 of a powder scoop or one soft chew — roughly 900 mg of mucopolysaccharides from the powder against 250 mg from the chew, about 3.6 times as much of the chondroitin-and-HA fraction at the same body weight. Glucosamine is closer (about 469 mg versus 500 mg). Switching format for palatability is not switching like for like, and the herbs can’t be compared at all: the powder uses whole roots, the chews use extracts.
What a buyer can and cannot verify
| What the label tells you | What it doesn’t |
|---|---|
| Exact mg of glucosamine HCl per serving, in every format | The split between chondroitin sulfate and hyaluronic acid — pooled into one “mucopolysaccharides” number |
| Nine named herbs with individual mg amounts | Any standardisation figure (e.g. curcuminoid %, harpagoside %), so extract potency is unknown |
| Source species for the key actives (shellfish glucosamine, porcine mucopolysaccharides) | Third-party assay or certificate-of-analysis data |
| Serving guidance by body weight, with initial and maintenance columns | Which format the trial behind the marketing actually used |
| NASC audit participation and US manufacturing from globally sourced ingredients | Full study data — inClover states “clinical data on file” |
That pooled mucopolysaccharide figure is the biggest gap, because chondroitin and hyaluronic acid are exactly what buyers want to compare across brands. Pricing is a separate moving target: inClover’s own comparison chart and its online store disagreed with each other in August 2026, so check the price at the point of sale.
Is Connectin really “clinically proven in 15 days”?
A real trial does exist. A write-up titled “Randomized Double-blinded, Placebo-controlled Multi-center Trial of an Orally Administered Composition (Connectin®) for the Treatment of Canine Osteoarthritis” was published by IVC Journal on 1 April 2014. It describes a five-site, GLP-following trial in which 46 dogs completed the study — 22 on Connectin and 24 on placebo — over eight consecutive weeks, with lameness examinations and Footscan pressure-plate gait analysis at day 28 and day 56. The stated conclusion was statistically significant improvement in orthopedic evaluation parameters versus placebo, specifically for lameness, willingness to hold the contralateral limb, and weight bearing of the affected joint, with no significant changes in kidney function, liver function, hematology, or physical parameters.
Here is what could not be verified as of August 2026:
- No PubMed-indexed publication. A PubMed search for “Connectin” combined with dog or canine returns only records about connectin (titin), the elastic muscle protein — none about the supplement. No indexed, peer-reviewed publication of this trial was locatable.
- IVC Journal is a trade magazine, not an indexed peer-reviewed veterinary journal. The write-up carries a site-account byline rather than named study authors, and no DOI. It credits a Colorado State University statistician in its acknowledgements.
- The write-up does not report a 15-day result. Owners completed weekly assessment forms from day 7, but the only reported outcomes come from the veterinary examinations and pressure-plate readings taken on day 28 and day 56. The phrase “15 days” does not appear in the text.
- The institution attribution is inconsistent. inClover’s “Our Science” page states the company worked with “Massey University Veterinary school” on “force plate clinical studies.” The IVC write-up describes a five-site multi-centre trial using a Footscan pressure plate and does not mention Massey University.
- The write-up’s own conclusion notes that owner assessment did not differ significantly between the Connectin and placebo groups. The significant findings were on veterinarian-scored orthopedic parameters. That is a meaningful distinction, because what an owner notices at home is usually what they are paying for.
None of this means Connectin doesn’t help dogs. It means the phrase “clinically proven” is doing more work than the publicly available evidence can carry. inClover itself footnotes the claim with “Verified by independent veterinary researchers. Clinical data on file” — an acknowledgement that the supporting dataset is not public.
What does independent research say about Connectin’s ingredients?
The headline ingredients have the weakest evidence, and the herb with the best canine data is not in the formula.
| Marketing framing | What independent research actually supports |
|---|---|
| Glucosamine, chondroitin and HA are “the 3 key building blocks important for joints” | Plausible, but clinically inconsistent. Merck states that a systematic review and meta-analysis “found no evidence of a beneficial effect” in dogs and cats. A 2022 meta-analysis of 72 trials reported a “very marked non-effect” of chondroitin-glucosamine nutraceuticals for pain management. Not all findings are negative: a 2007 UCD Dublin trial in 35 dogs reported significant improvement in pain, weight-bearing and severity scores by day 70 — though it was positive-controlled against carprofen with no placebo arm, and onset was slower than with carprofen. |
| Hyaluronic acid is “the joint’s lubricant” | Merck is direct on commercial HA products: their benefit in treating osteoarthritis “remains questionable.” |
| Nine herbs form an “effective delivery system” | Turmeric and devil’s claw have supportive data at meaningful doses, but the chews list 2.5 mg turmeric extract and 6.8 mg devil’s claw extract with no standardisation published, and canine trials used substantially larger amounts. Boswellia — arguably the herb with the best canine osteoarthritis data — is not in Connectin. |
| A joint supplement is the core of joint care | Every current guideline puts something else first. Merck calls weight optimisation “the primary preventive method to slow development of OA in dogs,” and notes EPA supplementation has shown improved gait and an NSAID-sparing effect. AAHA (2022) and COAST (2023) both frame care as multimodal. |
If you want the underlying mechanisms rather than the summary, we cover how glucosamine is absorbed and used in dogs separately, and you can compare dog arthritis supplements side by side to see how Connectin’s disclosure stacks up against products like Dasuquin Advanced and its published research.
How long before you’d realistically see anything?
Supplement timelines are the most oversold part of this category. Set expectations against what the research and the label describe:
| Time on product | What the evidence base suggests |
|---|---|
| Days 1–14 | Nothing reliable. inClover cites an average of 15 days, but the published write-up reports no outcome data before day 28. Changes this early are hard to separate from weather, activity, or wishful observation. |
| Weeks 3–4 | The first reported assessment point in Connectin’s own trial (day 28) — the first honest place to look. |
| Weeks 8–10 | The 2007 canine glucosamine/chondroitin trial found significant improvement by day 70; Connectin’s trial ran to day 56. The label also runs its “initial” serving column for 2–4 months. |
| No change by ~12 weeks | A reasonable point to stop, reassess with your vet, and consider options with stronger evidence. |
Track something measurable rather than a general impression — time to rise from lying down, willingness to take stairs, or how far into a walk stiffness appears. Merck notes that validated instruments such as the Canine Brief Pain Inventory and LOAD exist precisely because owner impressions drift.
Common mistakes owners make with Connectin
Switching formats and assuming the dose carried over. A maintenance scoop of powder and a maintenance soft chew are not equivalent on mucopolysaccharides. Re-read the weight chart when you change format.
Reading “clinically proven” as “will work for my dog.” Even in the trial inClover cites, the group-level benefit appeared on vet-scored measures while owner assessment did not separate from placebo.
Skipping the shellfish check. The glucosamine is shellfish-derived — mention that to your vet if your dog has reacted to shellfish-based products.
Treating a supplement as the whole plan. Weight, controlled exercise, traction on slippery floors and, where appropriate, prescription analgesia carry far more evidence — and there are practical ways to help a dog with arthritis at home that cost nothing.
Starting it because a dog “seems slow” without a diagnosis. Limping and reluctance to jump can come from cruciate injury, spinal disease, tick-borne illness or bone tumours, and a supplement won’t touch any of those. Our guide to recognising and managing dog joint pain covers what to look for.
Combining herbs with medications without telling the vet. Devil’s claw is generally listed as contraindicated in animals with gastric or duodenal ulceration, and flagged for caution alongside anticoagulants. Connectin contains it in all four formats.
When to call your vet
Book an appointment rather than reaching for a supplement if your dog shows:
- Sudden, non-weight-bearing lameness, or lameness that appears overnight
- A joint that is hot, visibly swollen, or painful to light touch
- Lameness with fever, lethargy, or loss of appetite
- Rapid deterioration in mobility over days rather than months
- Yelping when picked up, or new reluctance to be handled
- Any neurological sign — knuckling, dragging a paw, wobbling, or loss of bladder control
- Vomiting, diarrhoea, or appetite loss after starting any new supplement
Also call before starting Connectin if your dog is pregnant or nursing, has a history of gastrointestinal ulceration, liver or kidney disease, or a bleeding disorder, or takes NSAIDs, anticoagulants or cardiac medication. Ask about the whole plan, not just the supplement — weight and analgesia are where the strongest evidence lives.
Frequently asked questions
What is Connectin for dogs?
Connectin is a hip and joint supplement made by inClover Research. It combines glucosamine HCl, a porcine-sourced blend of chondroitin sulfate and hyaluronic acid, and nine herbs including yucca, turmeric, ginger, nettle and devil’s claw. It is sold as a powder, soft chews, crunchy tablets, and a concentrated chew for dogs over 70 lb.
Is Connectin clinically proven?
A randomised, placebo-controlled trial in 46 dogs was written up in IVC Journal in 2014 and reported significant improvement in vet-scored orthopedic parameters versus placebo over eight weeks. However, no peer-reviewed, PubMed-indexed publication of that trial was locatable as of August 2026, IVC Journal is a trade publication rather than an indexed journal, and the write-up does not report a 15-day result or a significant difference in owner assessment.
How much glucosamine is in Connectin?
The published label lists 625 mg of glucosamine HCl per 8.5 g powder scoop, 500 mg per soft chew, 750 mg per large-dog chew, and 500 mg per crunchy tablet. The amount your dog receives depends on the weight-based serving on the label, so follow the product label or your veterinarian’s guidance.
How long does Connectin take to work?
inClover’s marketing cites an average of 15 days, but the earliest assessment in the trial it references was day 28. The label itself runs an initial serving level for 2–4 months. A realistic checkpoint is four weeks, with a fuller reassessment around eight to twelve weeks.
Is Connectin safe for dogs?
The published trial reported no significant differences in kidney function, liver function, hematology or physical parameters versus placebo over eight weeks, and inClover participates in the NASC programme. The glucosamine is shellfish-derived, and the formula contains devil’s claw, which is commonly listed as contraindicated with gastric or duodenal ulceration and used cautiously alongside anticoagulants. Discuss it with your vet before starting.
Can Connectin replace my dog’s arthritis medication?
No. Current veterinary guidance treats osteoarthritis as a multimodal problem in which weight optimisation, controlled exercise and prescription analgesia carry the strongest evidence. Never stop or reduce a prescribed medication without speaking to your veterinarian.
References
- inClover Research. “Canine Connectin.” Product and ingredient page. https://inclover.com/canine-connectin/
- inClover Research. “Our Science.” https://inclover.com/our-science/
- IVC Journal. “Randomized Double-blinded, Placebo-controlled Multi-center Trial of an Orally Administered Composition (Connectin®) for the Treatment of Canine Osteoarthritis.” 1 April 2014. https://ivcjournal.com/randomized-double-blinded-placebo-controlled-multi-center-trial-of-an-orally-administered-composition-connectin-for-the-treatment-of-canine-osteoarthritis/
- inClover Research. “Safety & Quality.” https://inclover.com/safety-quality/
- Epstein ME. “Osteoarthritis in Dogs and Cats.” Merck Veterinary Manual, professional version, full review October 2024, last updated August 2025. https://www.merckvetmanual.com/musculoskeletal-system/osteoarthritis-in-dogs-and-cats/osteoarthritis-in-dogs-and-cats
- Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. “A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis.” Int J Mol Sci. 2022;23(18):10384. DOI: 10.3390/ijms231810384. PMID: 36142319. https://doi.org/10.3390/ijms231810384
- Vandeweerd JM, Coisnon C, Clegg P, et al. “Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis.” J Vet Intern Med. 2012;26(3):448–456. DOI: 10.1111/j.1939-1676.2012.00901.x. PMID: 22404506. https://doi.org/10.1111/j.1939-1676.2012.00901.x
- McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. “Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis.” Vet J. 2007;174(1):54–61. DOI: 10.1016/j.tvjl.2006.02.015. PMID: 16647870. https://doi.org/10.1016/j.tvjl.2006.02.015
- Gruen ME, Lascelles BDX, Colleran E, et al. “2022 AAHA Pain Management Guidelines for Dogs and Cats.” J Am Anim Hosp Assoc. 2022;58(2):55–76. DOI: 10.5326/JAAHA-MS-7292. PMID: 35195712. https://doi.org/10.5326/JAAHA-MS-7292
- Cachon T, Frykman O, Innes JF, et al. “COAST Development Group’s international consensus guidelines for the treatment of canine osteoarthritis.” Front Vet Sci. 2023;10:1137888. DOI: 10.3389/fvets.2023.1137888. https://doi.org/10.3389/fvets.2023.1137888
Label details and formats were verified against inClover’s own product, science and safety pages and its online store in August 2026, and may change.
Veterinary disclaimer: This article is for general information and is not veterinary advice. It is not intended to diagnose, treat, cure or prevent any disease. Always consult a licensed veterinarian before starting, changing or stopping any supplement or medication for your dog, particularly if your dog is pregnant, nursing, has an existing health condition, or is receiving other medication.